Paraoxonase genotypes, lipoprotein lipase activity, and HDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1243-1249

  Nevin, David N ^a   Zambon, Alberto ^a   Furlong, Clement E ^b   Richter, Rebecca J ^b   Humbert, Richard ^b   Hokanson, John E ^a,b   Brunzell, John D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoproteinA II; apolipoproteinA I; arylesterase; hepatic lipase; paraoxon

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARYLESTERASE; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029836028     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1243     Document Type: Article

References (36)

1. Aldridge WN. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E-600) and its identity with the A-esterase of mammalian sera. Biochem J. 1953;53:117-124.
2. Eckerson HW, Wyte CM, La Du BN. The human paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126-1138.
3. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet. 1988;43:230-238.
4. Playfer JR, Eze CL, Bullen MF, Evans DAP. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J Med Genet. 1976;13:337-342.
5. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991;30:10141-10149.
6. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 1993;3:73-76.
7. Adkins S, Can KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxon/arylesterase: Gin or Arg at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
8. Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 1991;40:277-282.
9. Rizack MA. Intravascular effect of heparin on plasma nonesterified fatty acid and triglyceride during alimentary lipemia. Proc Soc Exp Biol Med, 1960;104:111-113.
10. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193-199.
11. Kitchen BJ, Masters CJ, Winzor DJ. Effects of lipid removal on the molecular size and kinetic properties of bovine arylesterase. Biochem J. 1973;135:93-99.
12. Don MM, Masters CJ, Winzor DJ. Further evidence for the concept of bovine plasma arylesterase as a Hpoprotein. Biochem J. 1975;151:625-630.
13. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol. 1985;82B:675-677.
14. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
15. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984;259:12201-12209.
16. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JAK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33:832-839.
17. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 1993;13:147-153.
18. Marcovina S, Albers JJ. International Federation of Clinical Chemistry study on the standardization of apoproteins A-I and B. Curr Opin Lipid. 1991;2:355-361.
19. Iverius P-H, Brunzell JD. Human adipose tissue lipoprotein lipase: changes with feeding and relation to posteparin plasma. Am J Physiol. 1985;249:E107-E114.
20. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/ arylesterase. Anal Biochem., 1989;180:242-247.
21. Jacobs DR, Barrett-Conner E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics prevalence study. Am J Epidemio. 1982;116:878-885.
22. Ponz M, Solowiejcky D, Harpel B, Mory Y, Swartz E, Surrey S. Construction of human gene libraries from small amounts of peripheral blood: analysis of B-like globin genes. Hemoglobin. 1982;6:27-36.
23. Lipid Research Clinics Program. The Lipid Clinics Population Studies Data Book: the Prevalence Study. Bethesda, Md: National Institutes of Health; 1980;1:52-81.
24. Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, Disteche CM, Omiecinski CJ, Chapline C, Crabb JW, Humbert R. Human and rabbit paraoxonase: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interactions. 1993;87:35-48.
25. Geldmacher-von Mallinckrodt M, Diepgen TL. The human serum paraoxonase-polymorphism and specificity. Toxicol Environ Chem. 1988;18:79-196.
26. Magill P, Rao SN, Miller NE, Nicoll A, Brunzell J, St Hilaire J, Lewis B. Relationships between the metabolism of high-density and very- low-density lipoproteins in man: studies of apolipoprotein kinetics and, adipose tissue lipoprptein lipase activity. Eur J Clin Invest. 1982;12:113-120.
27. Kuusi T, Ehnholm C, Viikari J, Harkonen R, Vartiainen E, Puska P, Taskinen M-R. Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res. 1989;30:1117-1126.
28. Blatter Garin M-C, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, James RW. Quantification of human serum paraoxo- nase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
29. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vase Biol. 1995;15:89-85.
30. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites, Arterioscler Thromb Vase Biol. 1995;15:861-871.
31. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
32. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
33. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Mono- cyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039-2046.
34. Watson AD, Navab M, Hama SY, Sevenian A, Prescott SM, Stafforini DM, Mclntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized-low density lipoprotein. J Clin Invest. 1995;95:774-782.
35. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms, oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
36. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.